<scp> <i>MET</i> </scp> gene amplification is a mechanism of resistance to entrectinib in <scp>ROS1</scp> + <scp>NSCLC</scp>-Reference-Cited by-同舟云学术

MET gene amplification is a mechanism of resistance to entrectinib in ROS1 + NSCLC

Published:2022-09-13 Issue:21 Volume:13 Page:3032-3041
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Tyler Logan C.¹^ORCID,Le Anh T.¹,Chen Nan¹,Nijmeh Hala²,Bao Liming²,Wilson Timothy R.³,Chen David³,Simmons Brian³,Turner Kristen M.⁴,Perusse Dean⁴,Kasibhatla Shailaja⁴,Christiansen Jason⁴,Dudek Arkadiusz Z.⁵⁶,Doebele Robert C.¹

Affiliation:

1. Department of Medicine—Division of Medical Oncology University of Colorado—Anschutz Medical Campus Aurora Colorado USA

2. Department of Pathology University of Colorado—Anschutz Medical Campus Aurora Colorado USA

3. Genentech, Inc. South San Francisco California USA

4. Boundless Bio, Inc. San Diego California USA

5. HealthPartners Cancer Center at Regions Hospital St. Paul Minnesota USA

6. Department of Medicine—Division of Hematology, Oncology and Transplantation University of Minnesota Minneapolis Minnesota USA

Funder

Bonnie J. Addario Lung Cancer Foundation

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14656

Reference61 articles.

1. Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule.

2. Characterization of an activated human ros gene;Birchmeier C;Mol Cell Biol,1986

3. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer

4. Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma

5. Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers;2024-01-20

2. Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments;Frontiers in Oncology;2024-01-11

3. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF;JCI Insight;2023-12-22

4. Analysis of CD74 Occurrence in Oncogenic Fusion Proteins;International Journal of Molecular Sciences;2023-11-05

5. Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution;npj Precision Oncology;2023-11-03